Clinical trial success depends on more than breakthrough science. Behind every investigational product is a complex supply chain that must ensure the right product, with the right label, reaches the right patient at the right time.
As clinical trials become increasingly global, personalized, and data-driven, sponsors need connected systems that eliminate manual processes, improve traceability, and support regulatory compliance across the entire clinical supply ecosystem.
That is why Loftware's strategic collaboration with Signant Health continues to evolve. Building on the integrated clinical supplies labeling solution first announced in 2024, the latest release of Loftware Cloud Clinical Trials 1.21 introduces significant enhancements to the Loftware Signant Health Labeling Connector, helping sponsors and clinical supply teams work more efficiently while strengthening visibility across critical labeling workflows.
Clinical trial labeling sits at the intersection of compliance, manufacturing, supply chain management, and patient safety. Even minor inefficiencies can create downstream challenges, from delayed shipments and inventory shortages to increased operational costs and potential disruptions to patient treatment schedules.
The original integration was designed to address these challenges by connecting clinical supplies management with compliant clinical labeling processes. The release extends this vision with new capabilities that improve data synchronization, inventory management, and operational scalability.
One of the most significant additions is real-time label stock inventory management. Clinical trial teams can now update label stock levels within Signant Health's GxP Inventory directly from Loftware Cloud Clinical Trials during label print and reprint activities.
This enhancement delivers a more accurate view of label stock consumption and availability across clinical supply operations. For sponsors, that means greater confidence that critical label stock is available when needed. For supply chain teams, it reduces the risk of inventory shortages, excess stock, and operational delays that could impact clinical study timelines.
The enhanced connector also supports advanced label stock tracking and lot genealogy capabilities, providing greater supply chain visibility and traceability from label stock allocation through to printed label production.
Clinical trials are dynamic by nature, and rework activities are often unavoidable. Historically, managing labeling requests associated with rework processes has required additional coordination and manual effort.
The release extends the integration to support clinical label print requests for rework operations, enabling the same integrated workflow used for manufacturing-related print requests.
By bringing rework processes into the existing workflow framework, sponsors can maintain greater consistency across operations, reduce administrative burden, and improve process control throughout the product lifecycle.
Managing changes to program, trial, and label data has long been a challenge in clinical operations. Manual updates introduce risk, especially when multiple systems are involved.
The integration expands master data management capabilities by allowing authorized GxP Inventory users to update or delete shared program, trial, and label records created through the integration.
This enhancement helps ensure that both systems remain synchronized while reducing manual intervention and the potential for data discrepancies. The result is greater operational accuracy and improved governance of clinical trial information across connected processes.
As trial designs become larger and more complex, scalability is increasingly important.
The release includes performance enhancements for Clinical Label Print Request and Clinical Label Print Request Approval workflows. These improvements support organizations managing large-scale studies by enabling efficient generation of print requests using stored randomization files containing up to one million kits.
For sponsors and CDMOs, this means greater confidence that clinical labeling processes can scale alongside program growth without creating bottlenecks.
The new release also introduces enhancements to Single Sign-On (SSO) capabilities. Customers using Microsoft Entra ID can now complete action verification and electronic signatures through OpenID.
By reducing integration complexity and addressing common IT security concerns, organizations can accelerate enterprise adoption while maintaining compliance and governance requirements.
Although many of these enhancements focus on operational processes, their impact extends far beyond internal efficiency.
Better visibility into label inventory helps reduce supply disruptions. Improved traceability supports compliance and product integrity. More efficient data management reduces administrative delays. Scalable workflows enable study teams to manage growing clinical programs more effectively.
Ultimately, these improvements help clinical trial sponsors maintain continuity of supply and ensure investigational products can reach patients when and where they are needed. By connecting clinical supplies management with compliant clinical labeling, Loftware and Signant Health are helping organizations reduce complexity while supporting better trial execution and patient experiences.
Clinical trials will continue to become more distributed, data-intensive, and patient-centric. Success will depend on the ability to connect critical processes across clinical supply operations while maintaining compliance, traceability, and operational efficiency.
Loftware and Signant Health have taken another step toward this vision, delivering deeper integration, enhanced visibility, and greater scalability for modern clinical trial supply chains. Discover how Loftware can help your organization reduce labeling complexity, strengthen clinical supply resilience, and support more efficient trial execution. Learn more →
